Gefitinib
2 brands · 2 companies · product forms
Opportunity snapshot
Who competes here
Top companies by brand count — concentrated market · leader share 50%
Price room
Only 2 trusted price points; variation not scored (low data).
Brands & products on the market
Sample of 1 live product for Gefitinib — each links to its own medicine page.
Why this score
Launch attractiveness
40% supply-gap(65) + 25% price-variation(0) + 20% low-competition(95) + 15% supply-disruption(0), damped by confidence(50). Higher = more attractive, less crowded opportunity.
Market saturation
2 canonical companies and 2 brands compete (saturation pegged at 30 companies / 150 brands).
Price room
Only 2 trusted price points; variation not scored (low data).
Regulatory risk
No DRAP alerts on this molecule's brands.
Confidence
Reduced by: few brands, sparse price data.
Packaged brief for this moderate opportunity?
Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.
See packaged reports All 3868 molecules